EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases

Christine Girges iD, Nirosen Vijiaratnam, Alexa King, Grace Auld, Rachel McComish, Kashfia Chowdhury, Gareth Ambler, Kate Maclagan, Patricia Limousin, Dilan Athauda, Huw R Morris, Vincenzo Libri und 2 weitere

Clinical Trials · 2026

DOI: 10.1177/17407745251387571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Trials, 2026. Verfasst von Christine Girges und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Movement Neurosciences, Institute of Neurology, University College London, London, UK. Hauptthemen laut MEDLINE: Depression, Parkinson Disease, Patient Reported Outcome Measures, Multiple System Atrophy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Defeat MSA, Van Andel Institute, cure parkinson's trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Depression can be an intrinsic part of neurodegeneration, or a reaction to the onset of motor or non-motor disability. Depression can also adversely influence an individual’s perception of their disease, independently of its severity or impact on function. Participant-reported outcome measures are recognised as an important adjunct to objective clinical trial data. Although severe depression is a frequent contraindication for trial participation, mild-to-moderate depressive symptoms could potentially influence the outcome of such questionnaires. We aimed to explore this within two interventional trials for Parkinson’s disease (Exenatide PD3; NCT04232969) and multiple system atrophy (Exenatide MSA; NCT04431713).

Methods

Prior to investigational drug exposure, participants completed either the Patient Health Questionnaire or Beck Depression Inventory-II, which allowed us to dichotomise them into two groups (normal or mild-to-moderately elevated burden of depressive symptoms). Participants with Parkinson’s self-completed the Movement Disorder Society Sponsored Revision of the Unified Parkinson’s disease Rating Scale Parts 1b and 2, Parkinson’s Disease Questionnaire-39, Non-motor Symptoms Scale and EQ-5D-5L, while participants with multiple system atrophy self-completed a Quality of Life scale and had assistance with completing the Unified Multiple System Atrophy Rating Scale Part 1. The Movement Disorder Society Sponsored Revision of the Unified Parkinson’s Disease Rating Scale Part 3 and Unified Multiple System Atrophy Rating Scale Part 2 provided objective, clinician-rated measures of motor severity.

Results

A mild-to-moderately elevated burden of depressive symptoms was identified in 32.5% (63/194) and 42.0% (21/50) of Parkinson’s and multiple system atrophy participants, respectively. Despite the normal and elevated groups being comparable in terms of disease duration and objective motor severity, those with a mild-to-moderately elevated burden of depressive symptoms self-reported worse disease impact. However, measures which involved clinician and/or carer input (Unified Multiple System Atrophy Rating Scale Part 1) were not influenced by co-existing depressive symptoms.

Conclusions

Mild-to-moderate depressive symptoms, below the threshold for diagnosing a depressive disorder, are associated with negative self-reporting, and such findings should be carefully considered when planning the design and analysis of trials in neurodegenerative diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DepressionParkinson DiseasePatient Reported Outcome MeasuresMultiple System AtrophyHumansSelf ReportMaleFemaleMiddle AgedAgedSeverity of Illness IndexQuality of LifePsychiatric Status Rating ScalesClinical Trials as Topic

Stichwörter der Autor:innen

Depressive symptomsclinical trialsneurodegenerative diseasesoutcome measures

Autor:innen und Institutionen

  • Department of Clinical and Movement Neurosciences, Institute of Neurology, University College London, London, UK.
  • Clinical Research Centre for Movement Disorders and Gait, Kingston Centre, Parkinson's Foundation Centre of Excellence, Monash Health, Cheltenham, VIC, Australia.
  • Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia.
  • The Comprehensive Clinical Trials Unit, University College London, London, UK.
  • Department of Statistical Science, University College London, London, UK.
  • The Francis Crick Institute, London, UK.

ORCID-Profile: Christine Girges

Förderung

  • Defeat MSA
  • Van Andel Institute
  • cure parkinson's trust
  • John Black Charitable Foundation
  • Efficacy and Mechanism Evaluation Programme

Zitieren

APA

Girges, C., Vijiaratnam, N., King, A., Auld, G., McComish, R., Chowdhury, K., Ambler, G., Maclagan, K., Limousin, P., Athauda, D., Morris, H. R., Libri, V., Foltynie, T., & Exenatide PD3 and MSA Trials Consortia (2026). Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases. Clinical Trials. https://doi.org/10.1177/17407745251387571

Vancouver

Girges C, Vijiaratnam N, King A, Auld G, McComish R, Chowdhury K, et al. Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases. Clinical Trials. 2026. doi:10.1177/17407745251387571

BibTeX
@article{Girges2026,
  author = {Girges, Christine and Vijiaratnam, Nirosen and King, Alexa and Auld, Grace and McComish, Rachel and Chowdhury, Kashfia and Ambler, Gareth and Maclagan, Kate and Limousin, Patricia and Athauda, Dilan and Morris, Huw R and Libri, Vincenzo and Foltynie, Thomas and Exenatide PD3 and MSA Trials Consortia, Exenatide PD3 and MSA Trials Consortia},
  title = {Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases},
  journal = {Clinical Trials},
  year = {2026},
  doi = {10.1177/17407745251387571}
}
Kostenlos starten →